Patent details
EP2229172 Title: TICAGRELOR FOR TREATMENT OF ABDOMINAL AORTIC ANEURYSMS
Basic Information
- Publication number:
- EP2229172
- PCT Application Number:
- PCT/SE/2008/051386
- Type:
- European Patent Granted for LU
- Legal Status:
- In force
- Application number:
- EP088573548
- PCT Publication Number:
- WO/2009/072967
- First applicant's nationality:
- Translation Language:
- EPO Publication Language:
- English
- English Title of Invention:
- TICAGRELOR FOR TREATMENT OF ABDOMINAL AORTIC ANEURYSMS
- French Title of Invention:
- TICAGRELOR POUR LE TRAITEMENT D'ANÉVRYSMES AORTIQUES ABDOMINAUX
- German Title of Invention:
- TICAGRELOR ZUR BEHANDLUNG VON BAUCHAORTENANEURYSMEN
- SPC Number:
Dates
- Filing date:
- 02/12/2008
- Grant date:
- 10/09/2014
- EP Publication Date:
- 10/09/2014
- PCT Publication Date:
- 11/06/2009
- Claims Translation Received Date:
- Translations Received Date (B1 EP Publication):
- Translations Received Date (B2 EP Publication):
- Translations Received Date (B3 EP Publication):
- Publication date:
- 22/09/2010
- EP B1 Publication Date:
- 10/09/2014
- EP B2 Publication Date:
- EP B3 Publication Date:
- Lapsed date:
- Expiration date:
- 02/12/2028
- Renunciation date:
- Revocation date:
- Annulment date:
Owner
- From:
- 02/12/2008
- Name:
- AstraZeneca AB
- Address:
- -, 151 85 Södertälje, Sweden (SE)
Agent
- Name:
- ARONOVA S.A.
- From:
- 20/10/2014
- Address:
- PO Box 327, 4004, ESCH-SUR-ALZETTE, Luxembourg (LU)
- To:
Inventor
- Name:
- MICHEL Jean-Baptiste
- Address:
- France (FR)
Priority
- Priority Number:
- 07301616
- Priority Date:
- 03/12/2007
- Priority Country:
- European Patent Office (EPO) (EP)
Classification
- Main IPC Class:
- A61K 31/519;
Annual Fees
- Annual Fee Due Date:
- 31/12/2025
- Annual Fee Number:
- 18
- Annual Fee Amount:
- 262 Euro
- Expected Payer:
- Last Annual Fee Payment Date:
- 28/11/2024
- Last Annual Fee Paid Number:
- 17
- Last Annual Fee Paid Amount:
- 246 Euro
- Payer:
- CPA GLOBAL THE IP PLATFORM
| Filing date | Document type | Number of pages |
|---|